Frazier Management’s Vaxcyte PCVX Stock Holding History

Frazier Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,309,554	Closed	-$54.9M	–	20
2021 Q4	$54.9M	Hold	2,309,554	–	–	4.23%	7
2021 Q3	$58.6M	Hold	2,309,554	–	–	4.69%	6
2021 Q2	$52M	Hold	2,309,554	–	–	4.79%	8
2021 Q1	$45.6M	Hold	2,309,554	–	–	3.66%	7
2020 Q4	$61.4M	Hold	2,309,554	–	–	4.73%	6
2020 Q3	$114M	Hold	2,309,554	–	–	10.24%	3
2020 Q2	$73M	Buy	+2,309,554	New	+$74.3M	6.41%	4

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management's PCVX Position: Q1 2022 in Review

Frazier Management sold out of Vaxcyte (PCVX) in Q1 2022, closing a stake of 2,309,554 shares — an estimated $54.9M sold.

Frazier Management first reported a position in PCVX in Q2 2020 and held it in 7 quarters. The position peaked at $114M in Q3 2020. 88 funds tracked by Wall St. Rank hold PCVX as of Q1 2022.

Frazier Management reported no remaining Vaxcyte position as of Q1 2022 after selling out during the quarter.
Frazier Management sold 2,309,554 Vaxcyte shares in Q1 2022, an estimated $54.9M.
Frazier Management first reported a position in Vaxcyte in Q2 2020 and held it in 7 quarters.
Frazier Management's Vaxcyte position peaked at $114M in Q3 2020.
88 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.